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Compounds containing 4-aminoselenolo[3,2-d] pyrimidine in a novel tetracycIic condensed quinoline system
viz. pyrimido[4',5':4,5]selenolo [2,3-b]quinoline have been synthesized. Dimroth rearrangement of this new
condensed diazine system is studied. Biological study shows that while all compounds are active against collagen
induced blood platelet aggregation, they are found to be inactive against ADP induced blood platelet aggregation.
Considerable effort has been devoted in recent
years in search of inhibitors of blood platelet
aggregation 1 Among the structures of reported
inhibitors, 4-aminothieno[2,3-dJ pyrimidine
structure is gaining increasing importance.' Since
4-aminoselenolo[2,3-dJpyrimidine is isosteric with
4-aminothieno[2,3-d]pyrimidine it appeared to be
of interest to synthesize 4-aminopyrimido-[4', 5': 4,
5]selenolo[2, 3-b] quinoline and its derivatives
with a view to evaluating their blood platelet
disaggregation properties. 4-Aminopyrimido [4',
5': 4, 5]selenolo[2, 3-b ] quinoline 4 represents a
new class of condensed quinoline containing 4-
aminoselenolo[3, 2-dJpyrimidine structure and
could be looked upon as a new class of condensed
diazine. Diazines are known to undergo Dimroth
rearrangement which consists of hydrolytic ring
opening followed by rotation and recyclization
with a net result of migration of an alkyl or aryl
group from heterocyclic nitrogen to a-amine or
imine group. This rearrangement has been studied
in various condensed pyrimidine systems like,
quinazoline, purine, pteridine, benzofuro[2,3-b]-
pyrimidine and pyrimidothieno quinoline':". We
report herein the synthesis of the 4 and its
derivatives 5-12 and Dimroth rearrangement of
compounds 21a-c (Table I)
The strategy adopted for the synthesis of 4 is
essentially the same as the one developed by us for
the synthesis of pyrimido[4',5':4,5]selenolo[2,3-
b]quinolin-4(3H)-one 188• The only difference
being, instead of ethyl chloroacetate, chIoro-
acetonitrile was condensed with 3-cyanoquinolin-
2(1H)-selenone 1 in presence of 5% aq. KOH. The
resulting 2-cyanomethylseleno quinoline-3-
carbonitrile 2 was subjected to Thorpe-Ziegler type
cyclization by stirring with aq. KOH to get 2-
cyano-3-aminoselenolo[2,3-b]quinoline 3. The
same product 3 was also obtained directly from
selenone 1 using KOH of high concentration.
Structures of all these compounds were confirmed
by spectral and analytical data. Selenoloquinoline
3 on heating with formamide underwent
cyclocondensation to yield quinoline 4. Formation
of pyrimidine ring was confirmed on the basis of
spectral and analytical data. IR spectrum of 4 does
not show characteristic -CN bands at 2220 and
2260 cm" of the starting material 3, instead two
bands at 3150 and 3350 cm " corresponding to NH2
stretching frequencies are seen. PMR spectrum
shows singlet at 8 9.3 ppm integrating for one
proton attributable to C-2 of pyrimidine ring".
Further the N-benzyl derivative 5 prepared by the
reaction of benzyl chloride on 4 was found to be
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Table.I-Characterization Data of Compounds
Compd Mol.formula Yield % Analysis (%) IR(Nujol) PMR(ppm)
[m.p.°C] (crystalization) Found (calc.) (vrnaxem")
solvent) C H N
5 C2JlI4N•Se 71 61.29 3.36 14.29 3100-3500 (CF3COOH): 8,5.0 (2H, s, CH2),
(242) Aq. DMF (61.53 3.58 14.35) & 1620(NH) 7.3 (5H,bs, Ar-H), 7.8-8.6 (4H, m, H-7,
H-8, H-9, H-I0), 8.9 (lH, s, H-II), 10.1
(IH, s, H-2).
6 CI9HI2N4Se 90 60.42 3.02 14.69 3150-3350 (CF3COOH):8,7.5-7.9 (5H, m, Ar-H),
(276) DMF (60.63 3.19 14.89) & 1610(NH) 7.9-8.6 (4H, m, H-7, H-8, H-9, H-lO), 9.2
(IH, s, H-II), 10.1 (IH, s, H-2).
7 CI7HI6N4Se 85 56.99 4.31 15.71 3100-3450 (CF3COOH): 8, 0.95 (3H, t, CH3),
(164) Aq. EtOH (57.30 4.49 15.73) & 1664(NH) 1.2-1.8 (4H, m, CH2-CH2), 3.95 (2H, g,
NCH2), 7.8-8.6 (4H, m, H-7,H-8, H-9,
H-IO),8.9 (IH, s, H-II), 10.1 (lH, s, H-2).
8 C1SH12N4Se 76 54.84 3.50 16.91 3150-3400 (CF3COOH): 8,1.5 (3H, t, CH3), 3.9 (2H,
(222) Aq. EtOH (54.87 3.65 17.07) & 1600 (NH) q, -NCH2), 7.8-8.4 (4H, m, H-7, H-8,
H-9, H-IO), 8.9 (IH, s, H-II), 10.1 (IH, s,
H-2).
9 C17HI6N.Se 76 57.71 4.58 15.71 (CDCI3): 8,1.4 (6H, t, 2CH3), 3.75 (4H,
(122) Aq. EtOH (57.30 4.49 15.73) q, 2CH2) 7.2-8.15 (4H, m, H-7, H-8,H-9,
H-lO), 8.65 (tH, s, H-II), 9.35 (IH, s,
H-2).
10 C18HI6N4Se 78 59.00 4.52 15.40 (CDCI3): 8, 1.8 (6H, bs, 3CH2), 3.9 (4H,
(158) DMF (58.69 4.34 15.21) bs, 2NC H2), 7.2-8.15 (4H, m, H-7, H-8,
H-9, H-IO), 8.9 (lH, s, H-II), 10.1 (nr, s,
H-2).
11 C17H1.N4OSe 88 55.35 3.84 15.07 (CDCI3): 8, 3.9 (8H, s, 4CH2), 7.2-8.2
(206) EtOH (55.13 3.78 15.13) (4H, m, H- 7, H-8, H-9, H-IO), 8.7 (IH, s,
H-II), 9.25 (IH, s, H-2).
12 C17HISNsSe 76 55.10 4.19 18.93 3350(NH) (CF3COOH): 8,2.8 (4H, bs CH2-NH-CH2),
(209) EtOH (55.28 4.06 18.97) 4.65 (4H, bs, CH2-N-CH2), 7.9-8.6 (4H, m,
H-7, H-8, H-9, H-IO), 9.05 (IH, s, H- II),
10.2 (I H, s, H-2).
2Ia C2JlI.N.Se 84 61.68 3.49 14.28 3270(NH) (CF3COOH): 8,5.0 (2H, s, CH2), 7.4
(222) Benzene (61.53 3.58 14.35) I620(C=N) (5H, s, Ar-H), 7.8-8.6 (4H, m, H-7, H-8,
H-9, H-IO), 8.8 (tH, s, H-II),9.9 (lH, s,
H-2).
2Ib CI9H12N4Se 82 60.82 3.23 14.80 3250(NH) (CF3COOH): '0,7.7 (5H, s, Ar-H),
(203) DMF (60.63 3.19 14.89) I640(C=N) 8.05-8.75 (4H, m, H-7, H-8, H-9, H-IO),
9.3 (tH, s, H-II), 9.9 (tH, s, H-2).
2Ie C17HI6N4Se 80 57.20 4.90 15.23 3250(NH) (CF3COOH): 8, 1.05 (3H, t, CH3),
(159) Benzene (57.30 4.49 15.73) I640(C=N) 1.6-2.2 (4H, m, CH2-CH2), 4.4 (2H, q,
NCH2), 7.9-8.8 (4H, m, H-7, H-8, H-9,
H-IO), 9.3 (IH, s, H)
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identical with the one obtained by the reaction of
benzylamine on 4-chloropyrimido[4', 5': 4, 5]sele-
nolo[2, 3-b] quinoline 19 which was in turn
prepared by the reaction of phosphorus oxychlo-
ride on pyrimidoselenoloquinolone 188• N-
Substituted derivatives 5-12 were prepared by
reacting various amines with chIoro compound 19
(Scheme I).
As a typical example of aralkyl, aryl, and alkyl
group migration, Dimroth rearrangement of 3-
benzyl-, 3-phenyl- and 3-butylimino-3,4-dihydro-
pyrimido[4',5':4,5]selenolo[2,3-b] quinolines 21a-c
was undertaken. The key intermediate 2-
cyanoethoxymethyleneaminoselenolo[2, 3-b]qui-
noline 20 required for the synthesis of imines
21a-c was obtained by refluxing 3 with triethyl
orthoformate. The IR spectrum of 20 showed the
absence of bands due to primary amino group and
the PMR spectrum showed the signals with the
expected multiplicity due to ethoxy and N=CH-
protons at 0 1.5, 4.5 and 7.5 ppm, in addition to
aromatic protons. Compound 20 on treatment with
amines (benzylamine/aniline/n-butylamine) under-
went simultaneous aminolysis and cyclization to
give 3-benzyI/3-phenyl and 3-n-butyl-3,4-dihydro-
4-iminopyrimido [4', 5': 4, 5]selenolo[2, 3-b]qui-
nolines 21a-c. The involvement of CN group of 3
in the reaction was indicated by the absence of
band' at 2225cm-1 in the IR spectrum of 21a.
Structure of 21a was supported by the presence of
ne~bands at 3270 and 1620 em" due to NH and
C=N stretching frequencies. The PMR spectrum of
21a showed the disppearance of ethoxy protons
and appearance of new signal due to benzylic
protons. The imines 21a-c were then subjected to
Dimroth rearrangement by heating with aq. NaOH.
They underwent rearrangement by the cleavage of
C-N bond followed by recyclization to give
isomers 4-benzylamino/4-anilino and 4-n-butyl-
aminopyrimido [4', 5': 4,5]selenolo[2,3-b]quino-
lines 5, 6 and 7 respectively. The structure of the
rearranged product in each case was confirmed by
its synthesis via unambiguous routes as shown in
(Scheme II).
Inhibitory action of some of the synthesized
compounds (4, 7, 8, 9, 10 and 11) against blood
platelet aggregation was determined. We took this
opportunity to also to look at the inhibitory action
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us earlier!". Results indicate that compounds
exhibit inhibitory action against blood platelet
aggregation induced by collagen, while they were
almost inactive against the aggregation induced by
ADP(Table II). Among the compounds tested on
collagen induced aggregation, compound 14
exhibited highest inhibition at dose level 7.2 J.1M
(Figure 1).
Experimental Section
All melting points are uncorrected and were
taken in Thomas-Hoover capillary melting point
apparatus. Infrared spectra were recorded in
998
.,






































Figure I - Effect of inhibitor 14 on collagen induced human
blood platelet aggregation
Shimadzu infrared spectro photometer IR-435.
PMR spectra were recorded either on a FT-NMR
R-600, Brucker 270 MHz or varian T-60 model
using TMS as an internal standard. Blood platelet
aggregation was followed using a Chronolog-440
model dual channel aggregometer.
2-Cyanomethylselenoquinoline-3-carbonitrile
2. 3-Cyanoquinolin-2(1H)-selenone8 1 (1.165 g)
was dissolved in DMF (15 mL). To this solution
chloroacetonitrile (0.378 mL) and aq. KOH (5%,
5.6 mL) were added. The reaction mixture was
stirred for 15 min and diluted with water(50 mL).
The resultant solid was filtered, washed with water
and recrystallized from ethanol into pale yellow
needles yield 1.1 g (82%), m.p. 214°C. Anal:
Calcd for ClzH7N3Se: C,52.74; H, 2.56; N,15.38.
Found: C, 53.14; H, 2.74; N, 15.42%. IR (Nujol):
2220 (CN) and 2260 (CHzCN) em". PMR(CDCI3):
s 4.05(2H, s, SeCHz),7.2-8.2 (4H, m, H-5, H-6, H-
7, H-8); 8.6 (IH, s, H-4).
2-Cyano-3-aminoselenolo(2, 3-b)quinoline 3:
To a solution of 2 (0.54 g) in DMF (5 mL) was
added with stirring aq. KOH (10%, 5 mL). After
30 min, water(20 mL) was added to the reaction
mixture and the product was collected by filtration
and recrystallized from DMF into yellow shining
needles, yield 0.45g, (83%). m.p.264°C. Anal:
Calcd for CI2H7N3Se: C, 52.74; H, 2.56; N, 15.38
Found: C, 52.94; H, 2.66; N, 15.97%. IR (Nujol):
2210 (CN), 3150-3450 and 1650 (NH) cm'". PMR
(DMSO-d6): 07.4 (2H, bs, NHz), 7.7 (1H, t, H-7),
7.9 (lH, t, H-6), 8.05 (2H, dd, H-5, H-8), 9.15 (IH,
s, H-4).
This compound was also obtained from
compound 1 (2.33g) by using aq. KOH (10%,
20 mL).
4-Aminopyrimido[4', 5': 4, 5]selenolo[2, 3-
b) quinoline 4. A solution of 3 (lg) in formamide
(20 mL) was heated under reflux for 3 hr. The
reaction mixture was cooled and poured into cold
water. The product was collected by filtration,
washed with water, and recrystallized from acetic
acid into yellow needles, yield 0.8 g, 73% (did not
melt upto 340°C). Anal: Calcd for C13HgN4Se: C,
52.00; H, 2.66; N, 18.66. Found: C, 51.95; H, 2.65;
N, 18.38%. PMR (DMSO-d6): 0 7.55 (2H, bs,
NH2), 7.65 (IH, t, H-8), 7.95 (IH, t, H-9), 8.15
(lH, d, H-7), 8.35 (1H, d, H-I0), 8.6 (lH, s, H-l1),
9.3 (lH, s, H-2).
4-Chloropyrimido[4', 5': 4, 5]selenolo [2, 3-
b) quinoline 19. A mixture of compound 18 (3.0g)
and phosphorus oxychloride (50 mL) was heated
under reflux for 10 hr. After distilling off
phosphorus oxychloride (about 30 mL) under
reduced pressure, the reaction mixture was poured
into ice cold water. The product was collected by
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Table II-Effect of the synthetic compounds on blood platelet aggregation
Compd Cone. Aggregation Aggregating
No. (J1M) Slope Inhibition! agent
Control Compo Stimulation
(%)
4 3.8 2.12 2.84 +33.90 ADP
7 2.6 2.8 2.92 +4.30 ADP
8 2.9 2.8 2.52 -10.00 ADP
5.3 3.2 3.40 +13.75 ADP
9 2.7 2.8 2.8 0.00 ADP
10 2.7 2.8 2.8 0.00 ADP
5.3 3.20 3.2 0.00 ADP
11 2.9 2.8 2.6 -7.20 ADP
5.3 3.2 3.4 +12.5.0 ADP
14 2.9 1.9 1.35 -29.0 Collagen
7.2 1.0 0.166 -83.4 Collagen
15 2.6 1.9 1.6 -15.8 Collagen
6.7 1.0 1.0 0 Collagen
10.8 1.9 1.9 0 Collagen
21.6 1.6 1.12 -30.0 Collagen
27.0 1.0 0.57 -43.0 Collagen
17 2.7 1.9 1.9 0 Collagen
6.1 1.0 0.33 -67.0 Collagen
Stimulation and inhibition are indicated by (+) and (-) signs respectively.
filtration and recrystallized from acetonitrile into
pale yellow microneedles, yield: 3.0 g, 94%;
m.p.240°C. Anal: Calcd for C\3H6CIN3Se: C,
48.90; H, 1.88; N, 13.16. Found: C, 48.98; H, 1.68;
N, 13.26%. PMR (CDCI3): 0 7.2-8.2 (4H, m,
H-7, H-8, H-9, H-IO), 9.05 (IH, s, H-ll), 9.2 (IH,
s, H-2).
General method for the condensation of
amines with 19. To a solution of compound 19
(0.5 g) in DMF (15 mL) was added anhyd. K2C03
(0.5 g) and amine (0.5 g). The reaction mixture
was heated under reflux for 4-5 hr. The cold
reaction mixture was then poured into ice cold
water. The product was filtered and recrystallized
from suitable solvent. Characterization data for
compounds 5-12 are given in Table I.
General method for the condensation of
halides with 4. A solution of compound 4 (0.3 g)
in DMF (10 mL) was heated under reflux with
stirring for 5 hr after adding halide (0.5 g) and
anhyd. K2C03 (0.5 g). The reaction mixture was
cooled and poured into ice water(150 mL). The
resultant product was filtered, washed and
recrystallized from suitable solvent (Table I).
2-Cyano-3-ethoxymethyleneaminoselenolo[2,
3-b]quinoline 20. A solution of aminonitrile 3
(2.7 g) and triethyl orthoformate (50 mL) was
refluxed for 5 hr. Triethyl orthoformate was
distilled off under reduced pressure. The residue
obtained was dissolved in benzene and passed
through silica gel column. The product thus
obtained was recrystallized from benzene as pale
yellow fine needles, yield: 2.7 g (82%),
m.p.164°C. Anal: Calcd for C1sHI\N30Se: C,
54.71; H, 3.34; N, 12.76. Found: C, 54.74; H, 2.94;
N, 12.42%. PMR (CDCI3): 0 1.5 (3H, t, CH3,
J=6Hz); 4.5 (2H, q, CH2, J=6Hz); 7.5 (IH, s, N- .
CH); 7.6-8.2 (4H, m, H-5, H-6, H-7, H-8), 8.4 (IH,
s, H-4). .
3-Benzyl-3, 4-dihydro-4-iminopyrimido[4', 5'.:
4, 5]selenolo [2, 3-b]quinoline 21a. To a solution
of 20 (0.8 g) in dry benzene (50 mL) was added a
solution of benzylamine (0.3 g) in dry benzene (2.
mL) and stirred for 30 min when yellow solid
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separated. Stirring was continued for 2 hr. The
solid separated was collected and recrystallized
from benzene into yellow microneedles.
Similarly compounds 21b and' 21c were
obtained by treating compound 20 with aniline and
n-butylarnine respectively. Compound 4 was
obtained by passing dry ammonia gas (Table I).
4-Benzylaminopyrimido[4', 5': 4, 5]selenolo-
[2, 3-b]quinoline 5. (From Dimroth rearrange-
ment). Compound 21a (0.4 g) was suspended in
2N NaOH (aq. 30 mL) and the mixture was heated
with stirring at 100°C for 32 hr. Resulting solid 5
was recrystallized from DMF into microneedles.
Similarly 4-anilino compound 6 and 4-n-
butylamino compound 7 were obtained by heating
21b and 21c in 2N NaOH for 28 and 38 h
respectively. Elemental analysis, m.p, IR and PMR
spectra of these compounds were in agreement
with the authentic samples. (Table I).
Biological activity
Human blood was collected from a donor, non
smoker who was not on medication for at least 15
days prior to collection of blood. Platelet rich
plasma was prepared within 1 hr after collection of
blood. After incubation for 5 min the platelets
were treated with synthetic compound (5 ug)
dissolved in DMF or MeOH. After 2 min
aggregation was initiated by the addition of
aggregating agent ADP or collagen. The platelet
aggregation was followed atleast for 5 min. The
aggregation pattern was recorded on an omniscribe
recorder. The influence of the synthetic compound
on aggregation was evaluated by the difference in
the slope of the curves obtained in presence and
absence of the test compound. Initially, the effect
of the solvent on platelet aggregation was also
recorded in the presence of the solvent alone on
platelet aggregation. Concentration, slope and
inhibition activity of some active compounds are
given in Table II.
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